UPDATE: Northland Capital Markets Starts NovoCure Ltd. (NVCR) at Outperform, Sees a Near Double

September 23, 2020 7:18 AM EDT
Get Alerts NVCR Hot Sheet
Price: $224.43 +1.77%

Rating Summary:
    7 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 11 | New: 51
Trade Now! 
Join SI Premium – FREE

(Updated - September 23, 2020 7:22 AM EDT)

(updated to add analyst comments)

Northland Capital Markets analyst Jason Wittes initiates coverage on NovoCure Ltd. (NASDAQ: NVCR) with an Outperform rating and $200 price target.

The analyst commented, "We are initiating NVCR with an Outperform and $200 Price Target. The company's TTF technology is already approved for GBM and MPM, two of the most difficult to treat cancers, and demonstrated efficacy and safety in almost every solid tumor type and synergy with other therapies--a true fourth modality in the fight against cancer. 2021 is set up with multiple late stage interim and final readouts, which should drive valuation as investors better account for a significant pipeline."

For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.

Shares of NovoCure Ltd. closed at $104.15 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage